EGFR-targeted therapy

Experimental Cell Research

Volumn 317, Issue 19, 2011, Pages 2765-2771

  Vecchione, Loredana ^a,b,d   Jacobs, Bart ^a,b   Normanno, Nicola ^c   Ciardiello, Fortunato ^d   Tejpar, Sabine ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anti EGFR inhibitors; Colorectal cancer; EGFR signaling; Molecular subgroups; Oncogenic dependency; Personalized cancer therapy

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER;

CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CODON; COLORECTAL CANCER; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 80455173816     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.08.021     Document Type: Review

References (61)

1. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
2. Fiske W.H., Threadgill D., Coffey R.J. ERBBs in the gastrointestinal tract: recent progress and new perspectives. Exp. Cell Res. Feb 15 2009, 315(4):583-601. (Epub 2008 Nov 7).
3. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18:581-592.
4. Poston G.J., Figueras J., Giuliante F., Nuzzo G., Sobrero A.F., Gigot J.F., Nordlinger B., Adam R., Gruenberger T., Choti M.A., Bilchik A.J., Van Cutsem E.J., Chiang J.M., D'Angelica M.I. Urgent need for a new staging system in advanced colorectal cancer. J. Clin. Oncol. 2008, 26:4828-4833.
5. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert B.A., Smits A.A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319:525-532.
6. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129.
7. Rosen N. Molecular biology of gastrointestinal cancers. Cancer-Principles and Practice of Oncology 1997, 971-979. Lippincott Williams & Wilkins. 5th edn. V.T.J. De Vita, S. Hellman, S.A. Rosenberg (Eds.).
8. Wood L.D., Parsons W.D., Jones S., Lin J., Sjöblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson J.K.V., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V.K., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., Vogelstein B. The genomic landscape of human breast and colon cancers. Science Nov 16 2007, 318(5853):1108-1113.
9. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer Sep 2001, 37(Suppl. 4):S3-S8.
10. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. Feb 2001, 2(2):127-137. (Review).
11. Roberts R.B., Min L., Washington M.K., et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. Feb 5 2002, 99(3):1521-1526. (Epub 2002 Jan 29).
12. Erwin C.R., Helmrath M.A., Shin C.E., Falcone R.A., Stern L.E., Warner B.W. Intestinal overexpression of EGF in transgenic mice enhances adaptation after small bowel resection. Am. J. Physiol. 1999 Sep, 277(3 Pt 1):G533-G540.
13. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature May 14 2009, 459(7244):262-265. (Epub 2009 Mar 29).
14. Sato T., van Es J.H., Snippert H.J., Stange D.E., Vries R.G., van den Born M., Barker N., Shroyer N.F., van de Wetering M., Clevers H. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature Jan 20 2011, 469(7330):415-418. (Epub 2010 Nov 28).
15. Karamouzis M.V., Grandis J.R., Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007, 298:70-82.
16. Gridelli C., Bareschino M.A., Schettino C., Rossi A., Maione P., Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007, 12:840-849.
17. Messersmith W.A., Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?. Clin. Cancer Res. 2007, 13:4664-4666.
18. Sridhar S.S., Seymour L., Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003, 4:397-406.
19. Galizia G., Lieto E., De Vita F., Orditura M., Castellano P., Troiani T., Imperatore V., Ciardiello F. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007, 26:3654-3660.
20. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22:1201-1208.
21. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23:1803-1810.
22. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
23. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., Van Boom J.H., Van der Eb A.J., Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327:293-297.
24. Santini D., Loupakis F., Vincenzi B., Floriani I., Stasi I., Canestrari E., Rulli E., Maltese P.E., Andreoni F., Masi G., Graziano F., Baldi G.G., Salvatore L., Russo A., Perrone G., Tommasino M.R., Magnani M., Falcone A., Tonini G., Ruzzo A. High concordance of Kras status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008, 13:1270-1275.
25. Artale S., Sartore Bianchi A. Mutations of Kras and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 2008, 26:4217-4219.
26. Catalogue of Somatic Mutations in Cancer Wellcome Trust Sanger Institute, [cit January 15, 2010] Available from:. http://http//www.sanger.ac.uk/genetics/CGP/cosmic/.
27. Schubbert S., Shannon K., Bollag G. Hyperactive ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
28. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
29. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., Bastit L., Killian A., Sesboüé R., Tuech J.J., Queuniet A.M., Paillot B., Sabourin J.C., Michot F., Michel P., Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 2007, 96:1166-1169.
30. De Roock W., Piessevaux H., De Schutter J., Janssens M., De Hertogh G., Personeni N., Biesmans B., Van Laethem J.L., Peeters M., Humblet Y., Van Cutsem E., Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19:508-515.
31. Karapetis C.S., Khambata-Ford S., Jonker D.K., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
32. Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
33. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
34. European Medicines Agency: Committee for Medicinal Products for Human Use May 2008 Plenary Meeting Monthly Report http://www.emea.europa.eu/pdfs/human/press/pr/27923508en.pd.
35. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., Donea S., Ludwig H., Schuch G., Stroh C., Loos A.H., Zubel A., Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:663-671.
36. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
37. Douillard J., Siena S., Cassidy J. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur. J. Cancer 2009, 7:S6. (suppl; abstr 10LBA).
38. De Roock W., Jonker D.J., Di Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., Lamba S., Arena S., Frattini M., Piessevaux H., Van Cutsem E., O'Callaghan C.J., Khambata-Ford S., Zalcberg J.R., Simes J., Karapetis C.S., Bardelli A., Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA Oct 27 2010, 304(16):1812-1820.
39. Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 2009, 361:98-99.
40. Di Nicolantonio F., Martini M., Molinari, Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
41. Loupakis F., Ruzzo A., Cremolini C., Vincenzi B., Salvatore L., Santini D., Masi G., Stasi I., Canestrari E., Rulli E., Floriani I., Bencardino K., Galluccio N., Catalano V., Tonini G., Magnani M., Fontanini G., Basolo F., Falcone A., Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 2009, 101:715-721.
42. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemo-refractory metastatic colorectal cancer: a retrospective Consortium analysis. Lancet Oncol. 2010, 11(8):753-762.
43. Roth A.D., Tejpar S., Delorenzi M., Yan P., Fiocca R., Klingbiel D., Dietrich D., Biesmans B., Bodoky G., Barone C., Aranda E., Nordlinger B., Cisar L., Labianca R., Cunningham D., Van Cutsem E., Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. Jan 20 2010, 28(3):466-474. (Epub 2009 Dec 14).
44. Roth A.D., Tejpar S., Delorenzi M., Yan P., Fiocca R., Klingbiel D., Dietrich D., Biesmans B., Bodoky G., Barone C., Aranda E., Nordlinger B., Cisar L., Labianca R., Cunningham D., Van Cutsem E., Bosman F. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69:1851-1857.
45. Prenen H., De Schutter J., Jacobs B., de Roock W., Biesmans B., Claens B., Lambrecht D., Van Cutsem E., Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 2009, 15:3184-3188.
46. Perrone F., Lampis A., Orsenigo M., Di Bartolomeo M., Gevorgyan A., Losa M., Frattini M., Riva C., Andreola S., Bajetta E., Bertario L., Leo E., Pierotti M.A., Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 2009, 20:84-90.
47. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L.L., Cavalli F., Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 2007, 97:1139-1145.
48. Peeters M., Oliner K.S., Parker A. Use of massively parallel, nextgeneration sequencing to identify gene mutations beyond Kras that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC). American Association for cancer research 101st Annual meeting, April 17-21 2010, Washington. Abstract number LB174.
49. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23:1803-1810.
50. Hecht J., Mitchell E., Baranda J., Malik I., Richards D., Navale L., D'Avirro P., Amado R. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFR). J. Clin. Oncol. 2006, 24:157s. (abstract).
51. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6:279-286.
52. Cappuzzo F., Finocchiaro G., Rossi E., Jänne P.A., Carnaghi C., Calandri C., Bencardino K., Ligorio C., Ciardiello F., Pressiani T., Destro A., Roncalli M., Crino L., Franklin W.A., Santoro A., Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 2008, 19:717-723.
53. Personeni N., Fieuws S., Piessevaux H., De Hertogh G., De Schutter J., Biesmans B., De Roock W., Capoen A., Debiec-Rychter M., Van Laethem J.L., Peeters M., Humblet Y., Van Cutsem E., Tejpar S. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin. Cancer Res. 2008, 14:5869-5876.
54. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., Tan B.R., Krishnamurthi S.S., Burris H.A., Poplin E.A., Hidalgo M., Baselga J., Clark E.A., Mauro D.J. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25:3230-3237.
55. Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., Fieuws S., Vandesompele J., Peeters M., Van Laethem J.L., Humblet Y., Pénault-Llorca F., De Hertogh G., Laurent-Puig P., Van Cutsem E., Tejpar S. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 2009, 27:5068-5074.
56. Tabernero J., Cervantes A., Rivera F., Martinelli E., Rojo F., von Heydebreck A., Macarulla T., Rodriguez-Braun E., Vega-Villegas M.Eugenia, Senger S., Ramos F.J., Roselló S., Celik I., Stroh C., Baselga J., Ciardiello F. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J. Clin. Oncol. 2010, 28:1181-1189.
57. Baker J.B., Dutta D., Watson D., Maddala T., Munneke B.M., Shak S., Rowinsky E.K., Xu L.A., Harbison C.T., Clark E.A., Mauro D.J., Khambata-Ford S. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. BJC 2011, 104:488-495.
58. D. Rhodes, W.L. Banka, A.M. Chinnaiyan. Gene expression modules associated with cetuximab response in metastatic colorectal cancer predict additional patient populations likely to respond. (Personal communication).
59. Tejpar S., Popovici V., Delorenzi M., Budinska E., Estrella H., Mao M., Yan P., Weinrich S., Van Cutsem E., Roth A. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J. Clin. Oncol. 2010, 28:15s. (suppl; abstr 3505).
60. Jonker D.J., Karapetis C., Harbison C., O'Callaghan C.J., Tu D., Simes R.J., Xu L., Moore M.J., Zalcberg J.R., Khambata-Ford S. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from NCIC CTG.CO.17-a phase III trial of cetuximab versus best supportive care (BSC) 2009. ASCO Ann Meeting Proc: Chicago, IL 2009, (Abstract 4016).
61. Dry J.R., Pavey S., Pratilas C.A., Harbron C., Runswick S., Hodgson D., Chresta C., McCormack R., Byrne N., Cockerill M., Graham A., Beran G., Cassidy A., Haggerty C., Brown H., Ellison G., Dering J., Taylor B.S., Stark M., Bonazzi V., Ravishankar S., Packer L., Xing F., Solit D.B., Finn R.S., Rosen N., Hayward N.K., French T., Smith P.D. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. March 15, 2010, 70(6).